Unicycive Therapeutics Statistics
Total Valuation
UNCY has a market cap or net worth of $75.92 million. The enterprise value is $50.46 million.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
UNCY has 119.71 million shares outstanding. The number of shares has increased by 172.97% in one year.
| Current Share Class | 119.71M |
| Shares Outstanding | 119.71M |
| Shares Change (YoY) | +172.97% |
| Shares Change (QoQ) | +18.86% |
| Owned by Insiders (%) | 5.31% |
| Owned by Institutions (%) | 18.43% |
| Float | 70.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 9.72 |
| P/TBV Ratio | 10.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.28 |
| Quick Ratio | 1.08 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -452.35 |
Financial Efficiency
Return on equity (ROE) is -2,028.11% and return on invested capital (ROIC) is -787.80%.
| Return on Equity (ROE) | -2,028.11% |
| Return on Assets (ROA) | -87.54% |
| Return on Invested Capital (ROIC) | -787.80% |
| Return on Capital Employed (ROCE) | -425.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.64M |
| Employee Count | 23 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.85% in the last 52 weeks. The beta is 2.15, so UNCY's price volatility has been higher than the market average.
| Beta (5Y) | 2.15 |
| 52-Week Price Change | -44.85% |
| 50-Day Moving Average | 0.58 |
| 200-Day Moving Average | 0.52 |
| Relative Strength Index (RSI) | 58.93 |
| Average Volume (20 Days) | 1,089,526 |
Short Selling Information
The latest short interest is 1.71 million, so 1.43% of the outstanding shares have been sold short.
| Short Interest | 1.71M |
| Short Previous Month | 1.52M |
| Short % of Shares Out | 1.43% |
| Short % of Float | 2.43% |
| Short Ratio (days to cover) | 2.07 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -32.12M |
| Pretax Income | -36.93M |
| Net Income | -37.82M |
| EBITDA | -32.10M |
| EBIT | -32.12M |
| Earnings Per Share (EPS) | -$0.56 |
Full Income StatementBalance Sheet
The company has $26.14 million in cash and $681,000 in debt, giving a net cash position of $25.46 million or $0.21 per share.
| Cash & Cash Equivalents | 26.14M |
| Total Debt | 681,000 |
| Net Cash | 25.46M |
| Net Cash Per Share | $0.21 |
| Equity (Book Value) | 7.43M |
| Book Value Per Share | 0.07 |
| Working Capital | 6.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.58 million and capital expenditures -$72,000, giving a free cash flow of -$28.65 million.
| Operating Cash Flow | -28.58M |
| Capital Expenditures | -72,000 |
| Free Cash Flow | -28.65M |
| FCF Per Share | -$0.24 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |